BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 10671676)

  • 1. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
    Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy for small cell lung cancer].
    Fukuoka M; Takada M; Masuda N; Furuse K; Saijo N; Ikegami H; Nishiwaki Y
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():225-31. PubMed ID: 7516450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating chemotherapy with cyclophosphamide/adriamycin/vincristine (CAV) and cisplatin/etoposide (PVP) against small cell lung cancer. Eastern Shikoku Lung Cancer Chemotherapy Group.
    Bando H; Takishita Y; Ogura T; Sone S; Shimizu E; Nakayama T; Doi H; Kobayashi M
    Jpn J Clin Oncol; 1991 Dec; 21(6):435-9. PubMed ID: 1666660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
    Payne DG; Murray N; Warde P
    Bull Cancer; 1994 Feb; 81(2):119-28. PubMed ID: 7894117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
    Urban T; Chastang C; Lebas FX; Duhamel JP; Adam G; Darse J; Bréchot JM; Lebeau B
    Cancer; 1999 Dec; 86(11):2238-45. PubMed ID: 10590363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of small cell lung cancer].
    Komiya T; Takada M
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1116-23. PubMed ID: 8751797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of small cell lung cancer].
    Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Ryu S; Sakai N; Yamamoto H; Masuda N; Takifuji N
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):966-72. PubMed ID: 2839116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive alternating chemotherapy regimen in small cell carcinoma of the lung.
    Markman M; Abeloff MD; Berkman AW; Waterfield WC
    Cancer Treat Rep; 1985 Feb; 69(2):161-6. PubMed ID: 2982490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
    J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
    Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
    Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer].
    Miyamoto H; Kawakami Y; Arimoto T; Asakawa M; Suzuki A; Fujikane T; Onodera S; Nakabayashi T; Yasuda S; Shimizu T
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1127-34. PubMed ID: 1647149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of lung cancer--state of the art in 2000].
    Nakanishi Y; Inoue K; Hara N
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1247-52. PubMed ID: 10945023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.